520 likes | 758 Views
Need for screening?. Deaths by cause in South Africa. SADHS 1998 Steyn et al J Hypertension 2001. ESRD Worldwide. Incidence increasing - 6 % every year: cost anticipated>1 trillion $ by 2020Population growth rate - 1.2%Prevalence worldwide 1,783,000Estimate 100-1500/million population89% on haemodialysis (1,222,000)11% on CAPD (149,000)412,000 post transplants.
E N D
1. Screening, Prevention and Intervention Programs for CRF in South Africa Sarala Naicker
Division of Nephrology
University of Witwatersrand
Johannesburg, South Africa
Chair, Africa Subcommittee
ISN COMGAN
Rabat 2 December 2005
Morocco
2. Need for screening?
3. In 2001, noncommunicable conditions were the leading cause of deaths in all WHO regions with the exception of Africa in 2001. Noncommunicable conditions caused 8.7 million deaths in Western Pacific region, 8.4 million deaths in the European region, and 7.2 million deaths in South-East Asia. In Americas 4.5 million deaths were caused by noncommunicable conditions. In Eastern Mediterranean region 1.9 million deaths were caused by noncommunicable conditions. In Africa communicable diseases, maternal and perinatal conditions and nutritional deficiencies were responsible for 7.6 million deaths. In 2001, noncommunicable conditions were the leading cause of deaths in all WHO regions with the exception of Africa in 2001. Noncommunicable conditions caused 8.7 million deaths in Western Pacific region, 8.4 million deaths in the European region, and 7.2 million deaths in South-East Asia. In Americas 4.5 million deaths were caused by noncommunicable conditions. In Eastern Mediterranean region 1.9 million deaths were caused by noncommunicable conditions. In Africa communicable diseases, maternal and perinatal conditions and nutritional deficiencies were responsible for 7.6 million deaths.
4. Deaths by cause in South Africa
6. ESRD Worldwide Incidence increasing - 6 % every year: cost anticipated>1 trillion $ by 2020
Population growth rate - 1.2%
Prevalence worldwide 1,783,000
Estimate 100-1500/million population
89% on haemodialysis (1,222,000)
11% on CAPD (149,000)
412,000 post transplants
7. RRT Prevalence Worldwide
9. Dialysis Costs in Africa Togo : $100 public, $200 private.
Kenya: $50 public, $100 private.
Benin: $120 public
Nigeria: $100 public $150 private.
Ghana: $100 public
Senegal: $100 public $200 private.
Mauritius: Free to citizens.
South Africa: Free to citizens but exclusions.
10. Renal Transplant Costs Kenya: Public $7,500.00
Private $15,000.00
Nigeria: Public $15,000.00
Private $20,000.00
Sudan: Public $15,000.00
South Africa: Private $20,000.00
11. CKD:A Clinical Action Plan
12. Who to screen? Whole population screening eg. Singapore, South India
High risk patients
13. Aetiology of Kidney Failure
14. Hypertension
15. Diabetic Nephropathy Zambia 23.8%
South Africa 14-16%
Egypt 12.4%
Sudan 9%
Ethiopia 6.1%
Amos et al (1997). Diabetic Medicine
16. BP Control in South Africa SA Demographic Health Survey 1998
>13000 adults
HPT prevalence 21.3%
<50% treated
<1/3 controlled
Steyn et al. J Hypertens 2001; 19:1717-1725
17. Study by Gauteng Health Department
18. Membranous GN 306 Black children with NS
43% with membranous GN
86.2% HBV antigens
19. Tackling the problems:Screening, Prevention,Intervention Diabetes
Hypertension
Glomerular Disease
20. Type 2 Diabetes Mellitus Diabetic Nephropathy among black South Africans:
Preliminary data
Screening January 2005 to March 2005
320 patients screened; 188 females; 132 males
37.7% had proteinuria
Linda Ezekiel, ISN Fellow; unpublished data
21. HIV and Renal Disease Asymptomatic patients screened: 617
Urinalysis
Proteinuria: 37 (6%)
Microalbuminuria: 32/ 90; persistent 7
Haematuria: 9
Histology
HIVAN 86.2% of proteinuric pts
HIVAN 85.7% of MA pts (6/7)
Han et al, EDTA Abstracts 2004
22. Urinalysis in HIV
575 HIV+ patients in OPD screened, ART-naive
219 male (38%) 356 female (62%)
Abnormal dipsticks 270(47%)
205 proteinuric (36%)
Microalbuminuria = 139 (24.2%)
persistent= 33(5.7%)
Overt proteinuria = 55 (9.6%)
Nephrotic syndrome=11 (1.9%)
Fabian, unpublished data
23. CDOPPP Pilot Phase 35% Patients With Renal Disease
25% Macroalbuminuria
10% Microalbuminuria
From 1998 SADHS -35.5% of men and 10.8% of women are smokers in Gauteng Province
Current smokers: 9-15%
Mean cholesterol 5.2mmol/L+3.8
24. Prevention Strategies Public health measures: antenatal care/HIV/ HBV/ health education- smoking, diet, exercise, HIV
Early detection of proteinuria and prevention of progression of chronic kidney disease in high risk patients
Prevention of CKD in public health clinics
Detection and Mx of HPT AND DM
Optimal utilisation of healthcare personnel
Partnerships: Govt, NKF, ISN, other
25. HBsAg in Children in S Africa
26. Impact of HBV vaccination on NS in children 1984 – 2001 119 children with HBV MN
aRR 0.25/ 105
1984 – 1994 0.22
2000 – 2001 0.03
pre-vaccine post-vaccine
0 – 4 years 0.16 0.00
5 – 10 years 0.46 0.09
Bhimma et al, 2002
27. Outcomes of ACEI therapy in HIVAN
28. CDOPPP Baseline Data1999 to 2005…..
29. Program Nurse Managers
30. Key Factors to monitor CDOPPP Group Highlight Australian support and reasons for choosing Australia initiallyHighlight Australian support and reasons for choosing Australia initially
31. Simplified Evidence Based Treatment Targets
32. No Significant difference in the distribution of BMI between the IC and the CC.No Significant difference in the distribution of BMI between the IC and the CC.
33. SBP and DBP change over time
34. Percent of patients at targets for glucose control
35. Albumin Creatinine Ratio (ACR) change over twenty months
36. Challenges Staff shortages
Overwhelmed by burden of patients
Delivery problems of drugs and infrastructure
Data capture quality and efficiency
Inadequate long term follow up and loss of patients
Lack of Motivation amongst staff
Showing participants the value of the program
Focusing on problems with patients / patient education
Improving patient care
Early detection of problems
Successful lowering of BP
Better understanding of problems
Link between 10 and 30 facilities
Education of staff, management and patients
Management gaining a better understanding of problems
Clinics with good follow up are doing well!
Management can see value of PHC
37. WHAT IS THE GLOBAL STRATEGY NEEDED IN THE DEVELOPING WORLD? Prevention
Identify apparently healthy subjects at risk of developing renal and cardiovascular diseases later in life
Build regional or national prevention strategies by developing therapeutic intervention programs; drugs should be freely available at low cost
Optimise HCW and community participation
Global partnerships
40. RRT in South Africa Private Sector: HD 80%; CAPD 20%
Public Sector
ARF
CRF: no/low cost if eligible for TP (National Health Policy); >1000 new patients/ year
HD : 60%
CAPD: 40%
TP 18% -CD: 60%
-LD: 40%
41. ESRD Resource Availability.
42. WHAT IS THE GLOBAL STRATEGY NEEDED IN THE DEVELOPING WORLD? RRT
Strategies to make dialysis affordable
Partnerships with govts/ dialysis providers/ NGOs
Initially for acute renal failure
Dialysis for chronic renal failure should be integrated with transplantation
43. Recommendations Public Education
Need for Legal Edict
Set-up Foundations to fund dialysis/ transplants for the needy; partnership with Govt, NGOs, other
Drug availability and possible subsidy
Training of HCW
Registry
Research and Development
44. Special thanks to… Dr Ivor Katz, South Africa
Dr Maung Han, South Africa
Dr June Fabian, South Africa
Dr Linda Ezekiel, ISN Fellow, Tanzania
Dr Ebun Bamgboye, Nigeria
Professor John Dirks, Canada
46. Numbers of doctors/ 100,000 Egypt 202 Algeria 84.6
Libya 128 Tunisia 70
South Africa 56.3 Morocco 46
Namibia 29.5 Kenya 13.2
Botswana 23.8 Congo Dem. 6.9
Nigeria 18.5 Cent Afr. Rep. 3.5
Sudan 9.0 Chad 3.3
Sierra Leone 7.3 Eritrea 3.0
Ghana 6.2 Ethiopia 2.0
Tanzania 4.1 Cameroon 7.4
Burkina Faso 3.4 Benin 5.7
Liberia 2.3 Niger 3.5
Togo 7.6 Uganda 3.0
Ivory Coast 9.0
47. Numbers of doctors per 100,000 Italy 554
Russian Federation* 421
Germany 350
France 303
USA 279
Canada 229
UK 164
Former Soviet States* >300
48. Glucose, HbA1c
49. BMI
50. Dialysis Patients World-wide (1996)
51. ESRD/RRT IN SOUTH AFRICA Prevalence ? 500 pmp
Population 46million
New patients treated annually: >1000
HD 42%
PD 40%: JHB peritonitis rate 1/>12pm
Tx 18%
Eligibility for chronic dialysis in public sector: renal transplant- Policy of National Health Dept
All patients receive dialysis for ARF in S Africa
Prevention programmes in infancy
52. DIALYSIS IN S AFRICA 2005